journal article·2026-02-07Open access

Functionalized Biomaterials in the Investigation of the Effects of Fluid Shear Forces in the Immune Regulation of Cancer Progression and Metastasis

Rayhaneh Afjei, Vassilios I. Sikavitsas

Abstract

As cancer mortality rates rise globally, malignancies have become the second leading cause of death. Recently, efforts have been made to understand the impact of the tumor microenvironment that involves fluid shear forces. Biomechanical stimulation, which uses shear stress to activate mechanosensitive ion channels, e.g., Piezo1, increases calcium influx into the intracellular space and activates T cells. Novel 3D cancer cultures with T cells have been proposed. Such models use cell/scaffold constructs to recapitulate interactions between cells and the extracellular matrix. In addition, flow perfusion bioreactors investigate the impact of fluid shear forces on immune and/or cancer cells. These bioreactors have biosensors that allow monitoring of immune cell activation. Furthermore, they provide a biomimetic environment for the study of the interaction of T cells and cancer cells. Hence, immune checkpoint inhibitors have demonstrated immunotherapeutic efficacy, but a single-target blockade has often proved insufficient. Co-delivery of CCL19 pDNA and the PD-1/PD-L1 interaction inhibitor BMS-1 using RGD-modified nanocarriers targeting tumor integrins enhanced local antitumor immunity. This review highlights recent insights into how fluid shear stress (FSS) regulates cancer progression and immune responses in three-dimensional in vitro models, with a focus on bioreactors and the surface modification of scaffold materials.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: 3D Printing in Biomedical Research · Erythrocyte Function and Pathophysiology · Cancer Cells and Metastasis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Chemical, Biological, and Materials Engineering, University of Oklahoma, Norman, OK 73019, USA

School of Electrical and Computer Engineering, University of Oklahoma, Norman, OK 73019, USA

Funding

Presbyterian Health Foundation

References (100+)

Show source-provided references
1. Qu, P., and Zhang, H. (2025). The dual role of Piezo1 in tumor cells and immune cells: A new target for cancer therapy. Front. Immunol., 16.10.3389/fimmu.2025.1635388 ↗
2. Circulating tumor cells: From new biological insights to clinical practice10.1038/s41392-024-01938-6 ↗
3. T cells in cancer: Mechanistic insights and therapeutic advances10.1186/s40364-025-00807-w ↗
4. CD8(+) T cells: Foot soldiers of the immune system10.1016/j.immuni.2011.07.010 ↗
5. Metabolic T-cell phenotypes: From bioenergetics to function10.1152/ajpcell.00478.2024 ↗
6. CD4+ T cell dysfunction in cancer10.1084/jem.20241417 ↗
7. Immune checkpoint inhibitors in cancer therapy: What lies beyond monoclonal antibodies?10.1007/s12032-025-02822-1 ↗
8. Cellular mechanoactivation of antigen-presenting cells and T cells for cancer immunotherapy10.1016/j.cobme.2025.100619 ↗
9. Cordeiro, S., Oliveira, B.B., Valente, R., Ferreira, D., Luz, A., Baptista, P.V., and Fernandes, A.R. (2024). Breaking the mold: 3D cell cultures reshaping the future of cancer research. Front. Cell Dev. Biol., 12.10.3389/fcell.2024.1507388 ↗
10. Mechanical signatures in cancer metastasis10.1038/s44341-024-00007-x ↗
11. Focus on mechano-immunology: New direction in cancer treatment10.1097/JS9.0000000000002224 ↗
12. Biomechanical forces in tissue engineered tumor models10.1016/j.cobme.2018.03.004 ↗
13. T Cell Development and Function10.1089/rej.2023.0015 ↗
14. T-cell development and the CD4–CD8 lineage decision10.1038/nri798 ↗
15. From thymus to tissues and tumors: A review of T-cell biology10.1016/j.jaci.2022.10.011 ↗
16. Localization, tissue biology and T cell state—Implications for cancer immunotherapy10.1038/s41577-023-00884-8 ↗
17. T cell migration, search strategies and mechanisms10.1038/nri.2015.16 ↗
18. T cells in health and disease10.1038/s41392-023-01471-y ↗
19. Wherry, E.J., and Kurachi, M. (2015). Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol., 15.10.1038/nri3862 ↗
20. Immune Checkpoint Molecules: A Review on Pathways and Immunotherapy Implications10.1002/iid3.70196 ↗
21. From tumor to tolerance: A comprehensive review of immune checkpoint inhibitors and immune-related adverse events10.5415/apallergy.0000000000000146 ↗
22. The blockade of immune checkpoints in cancer immunotherapy10.1038/nrc3239 ↗
23. Immune checkpoint signaling and cancer immunotherapy10.1038/s41422-020-0343-4 ↗
24. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy10.1158/2159-8290.CD-18-0367 ↗
25. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition10.1097/COC.0000000000000239 ↗
26. Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: Breakthroughs or backups10.1038/s41590-019-0512-0 ↗
27. The future of immune checkpoint therapy10.1126/science.aaa8172 ↗
28. PD-1 and its ligands in tolerance and immunity10.1146/annurev.immunol.26.021607.090331 ↗
29. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses10.1038/nri3108 ↗
30. LAG3 (CD223) as a cancer immunotherapy target10.1111/imr.12519 ↗
31. Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB110.1038/ni.2376 ↗
32. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity10.1038/ni1271 ↗
33. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function10.1016/j.ccell.2014.10.018 ↗
34. TIGIT and CD96: New checkpoint receptor targets for cancer immunotherapy10.1111/imr.12518 ↗
35. Response of cells and tissues to shear stress10.1242/jcs.260985 ↗
36. A systematic investigation of the effect of the fluid shear stress on Caco-2 cells towards the optimization of epithelial organ-on-chip models10.1016/j.biomaterials.2019.119521 ↗
37. Piezo1 and Piezo2 are essential components of distinct mechanically activated cation channels10.1126/science.1193270 ↗
38. Roles of mechanosensitive ion channels in immune cells10.1016/j.heliyon.2023.e23318 ↗
40. Endothelial cation channel PIEZO1 controls blood pressure by mediating flow-induced ATP release10.1172/JCI87343 ↗
41. Matrix stiffness induces epithelial-to-mesenchymal transition via Piezo1-regulated calcium flux in prostate cancer cells10.1016/j.isci.2023.106275 ↗
42. Hope, J.M., Dombroski, J.A., Pereles, R.S., Lopez-Cavestany, M., Greenlee, J.D., Schwager, S.C., Reinhart-King, C.A., and King, M.R. (2022). Fluid shear stress enhances T cell activation through Piezo1. BMC Biol., 20.10.1186/s12915-022-01266-7 ↗
43. Activation of apoptosis signalling pathways by reactive oxygen species10.1016/j.bbamcr.2016.09.012 ↗
44. Endothelial Piezo1 channels as sensors of exercise10.1113/JP274396 ↗
45. PIEZO ion channels: Force sensors of the interoceptive nervous system10.1113/JP284077 ↗
46. Piezo channels in the urinary system10.1038/s12276-022-00777-1 ↗
47. Mechanotransduction across the cell surface and through the cytoskeleton10.1126/science.7684161 ↗
48. Receptor-mediated cell mechanosensing10.1091/mbc.e17-04-0228 ↗
49. Cunyu, Z. (2024). The Resistance of Circulating Tumor Cells to Large Fluid Shear Stress in Hematogenous Dissemination by Reducing Mechanosensitivity via Nuclear Mechanosensing Mediated Myosin Cytoplasmic Redistribution. [Ph.D. Thesis, Hong Kong Polytechnic University].
50. Integrins in mechanotransduction10.1016/j.ceb.2013.05.006 ↗
51. Leukocytes as carriers for targeted cancer drug delivery10.1517/17425247.2015.966684 ↗
52. Multiplex quantitative analysis of stroma-mediated cancer cell invasion, matrix remodeling, and drug response in a 3D co-culture model of pancreatic tumor spheroids and stellate cells10.1186/s13046-019-1225-9 ↗
53. Dombroski, J.A., Hope, J.M., Sarna, N.S., and King, M.R. (2021). Channeling the Force: Piezo1 Mechanotransduction in Cancer Metastasis. Cells, 10.10.3390/cells10112815 ↗
54. Mechanosensitive Ion Channels: TRPV4 and P2X7 in Disseminating Cancer Cells10.1097/PPO.0000000000000312 ↗
55. Greenlee, J.D., Liu, K., Lopez-Cavestany, M., and King, M.R. (2022). Piezo1 Mechano-Activation Is Augmented by Resveratrol and Differs between Colorectal Cancer Cells of Primary and Metastatic Origin. Molecules, 27.10.3390/molecules27175430 ↗
56. Bryant, P., and Sikavitsas, V.I. (2023). Cancer Exosomes: An Overview and the Applications of Flow. Fluids, 8.10.3390/fluids8010007 ↗
57. Cellular geometry and epithelial-mesenchymal plasticity intersect with PIEZO1 in breast cancer cells10.1038/s42003-024-06163-z ↗
58. Superhydrophobic Array Devices for the Enhanced Formation of 3D Cancer Models10.1021/acsnano.4c08132 ↗
59. Ortiz-Otero, N., Marshall, J.R., Lash, B., and King, M.R. (2020). Chemotherapy-induced release of circulating-tumor cells into the bloodstream in collective migration units with cancer-associated fibroblasts in metastatic cancer patients. BMC Cancer, 20.10.1186/s12885-020-07376-1 ↗
60. Circulating Tumor Cells: Diagnostic and Therapeutic Applications10.1146/annurev-bioeng-062117-120947 ↗
61. Pinto, B., Henriques, A.C., Silva, P.M.A., and Bousbaa, H. (2020). Three-Dimensional Spheroids as In Vitro Preclinical Models for Cancer Research. Pharmaceutics, 12.10.3390/pharmaceutics12121186 ↗
62. Gene expression perturbation in vitro—A growing case for three-dimensional (3D) culture systems10.1016/j.semcancer.2005.06.009 ↗
63. Boucherit, N., Gorvel, L., and Olive, D. (2020). 3D Tumor Models and Their Use for the Testing of Immunotherapies. Front. Immunol., 11.10.3389/fimmu.2020.603640 ↗
64. Paolillo, M., Colombo, R., Serra, M., Belvisi, L., Papetti, A., Ciusani, E., Comincini, S., and Schinelli, S. (2019). Stem-Like Cancer Cells in a Dynamic 3D Culture System: A Model to Study Metastatic Cell Adhesion and Anti-Cancer Drugs. Cells, 8.10.3390/cells8111434 ↗
65. The relevance of using 3D cell cultures, in addition to 2D monolayer cultures, when evaluating breast cancer drug sensitivity and resistance10.18632/oncotarget.9935 ↗
66. Studies on oxygen availability and the creation of natural and artificial oxygen gradients in gelatin-methacryloyl hydrogel 3D cell culture10.1002/term.3344 ↗
67. Metabolic adaptation in hypoxia and cancer10.1016/j.canlet.2020.12.020 ↗
68. The therapeutic potential of three-dimensional multipotent mesenchymal stromal cell spheroids10.1186/s13287-017-0558-6 ↗
69. Comprehensive analysis of EMT-related genes and lncRNAs in the prognosis, immunity, and drug treatment of colorectal cancer10.1186/s12967-021-03065-0 ↗
70. Kuen, J., Darowski, D., Kluge, T., and Majety, M. (2017). Pancreatic cancer cell/fibroblast co-culture induces M2 like macrophages that influence therapeutic response in a 3D model. PLoS ONE, 12.10.1371/journal.pone.0182039 ↗
71. 3D Co-culture of Cancer-Associated Fibroblast with Oral Cancer Organoids10.1177/0022034520956614 ↗
72. CAR-T “the living drugs”, immune checkpoint inhibitors, and precision medicine: A new era of cancer therapy10.1186/s13045-019-0819-1 ↗
73. Epigallocatechin-3-gallate inhibits the growth of three-dimensional in vitro models of neuroblastoma cell SH-SY5Y10.1007/s11010-021-04154-w ↗
74. Eibl, R., and Eibl, D. (2010). Sensors in Disposable Bioreactors Status and Trends. Disposable Bioreactors, Springer.10.1007/978-3-642-01872-5 ↗
75. Fluorescence-based real time monitoring and diagnostics of recombinant Pichia pastoris cultivations in a bioreactor10.1002/btpr.2761 ↗
76. Design of a flow perfusion bioreactor system for bone tissue-engineering applications10.1089/107632703322066723 ↗
77. Fluid-induced low shear stress improves cartilage like tissue fabrication by encapsulating chondrocytes10.1007/s10561-015-9529-2 ↗
78. Regmi, S., Poudel, C., Adhikari, R., and Luo, K.Q. (2022). Applications of Microfluidics and Organ-on-a-Chip in Cancer Research. Biosensors, 12.10.3390/bios12070459 ↗
79. Caballero, D., Kundu, S.C., and Reis, R.L. (2022). Microfluidics for the Isolation and Detection of Circulating Tumor Cells. Microfluidics and Biosensors in Cancer Research: Applications in Cancer Modeling and Theranostics, Springer International Publishing.
80. Dynamic in vitro models for tumor tissue engineering10.1016/j.canlet.2019.01.043 ↗
81. Perfusion Flow Enhances Viability and Migratory Phenotype in 3D-Cultured Breast Cancer Cells10.1007/s10439-021-02727-w ↗
82. G9a inhibition by CM-272: Developing a novel anti-tumoral strategy for castration-resistant prostate cancer using 2D and 3D in vitro models10.1016/j.biopha.2022.113031 ↗
83. Is It Time to Start Transitioning From 2D to 3D Cell Culture?10.3389/fmolb.2020.00033 ↗
84. 2D and 3D cell cultures–A comparison of different types of cancer cell cultures
85. Microfluidic 3D cell culture: From tools to tissue models10.1016/j.copbio.2015.05.002 ↗
86. Avena, P., Zavaglia, L., Casaburi, I., and Pezzi, V. (2025). Perfusion Bioreactor Technology for Organoid and Tissue Culture: A Mini Review. Onco, 5.10.3390/onco5020017 ↗
87. Immunomechanobiology: Engineering the Activation and Function of Immune Cells with the Mechanical Signal of Fluid Shear Stress10.1109/RBME.2024.3505073 ↗
88. Fluid shear stress enhances dendritic cell activation10.1016/j.imbio.2023.152744 ↗
89. Enhanced and sustained T cell activation in response to fluid shear stress10.1016/j.isci.2024.109999 ↗
90. The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction10.1016/j.immuni.2016.07.009 ↗
91. The tumor microenvironment10.1016/j.cub.2020.06.081 ↗
92. Advances in tumor microenvironment and underlying molecular mechanisms of bladder cancer: A systematic review10.1007/s12672-024-00902-8 ↗
93. Mitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma10.1172/jci.insight.93411 ↗
94. Zhou, Q., Wei, S., Wang, H., Li, Y., Fan, S., Cao, Y., and Wang, C. (2023). T cell-derived exosomes in tumor immune modulation and immunotherapy. Front. Immunol., 14.10.3389/fimmu.2023.1130033 ↗
95. Suppressive effects of the obese tumor microenvironment on CD8 T cell infiltration and effector function10.1084/jem.20210042 ↗
96. Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy10.1016/j.cmet.2017.06.016 ↗
97. Exosomes in diagnostic and therapeutic applications of ovarian cancer10.1186/s13048-024-01417-0 ↗
98. Crews, D.W., Dombroski, J.A., and King, M.R. (2021). Prophylactic Cancer Vaccines Engineered to Elicit Specific Adaptive Immune Response. Front. Oncol., 11.10.3389/fonc.2021.626463 ↗
99. Engineering of Exosomes to Target Cancer Metastasis10.1007/s12195-019-00607-x ↗
100. Malignant effusions and immunogenic tumour-derived exosomes10.1016/S0140-6736(02)09552-1 ↗